Submission guidelines

Instructions for Authors

Manuscript Submission

Manuscript Submission

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Permissions

Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission

Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen.

Please ensure you provide all relevant editable source files. Failing to submit these source files might cause unnecessary delays in the review and production process.

Types of articles

The Brazilian Journal of Pharmacognosy accepts for publication original scientific work, reviews and communication articles written only in English.

• Original papers: Original papers are research articles describing original experimental results. The manuscript should be arranged in the following order: Graphical abstract, Title, Abstract, Keywords, Introduction, Material and methods, Results, Discussion, Authors’ contributions, Acknowledgements, References, Figures with Legends, Tables, Structural Formulae and Supplemental files (if applicable). Results and Discussion sections may appear as a combined ‘Results and Discussion’ section. The normal length of the main text of an Original Paper (excluding references, tables, figures and figure legends) is approximately 3,000 words. Longer manuscripts may be accepted only in exceptional and well justified cases.

•Short communications: This section will cover mainly the isolation of known compounds from new neotropical sources, or complementary results of on-going work. The text should be arranged as follows: Graphical abstract, Title, Abstract of 200 words, Keywords, Introductory Remarks, Material and Methods with brief experimental details without subheadings, Results and Discussion as one body of text without headlines, Acknowledgements, Authorship, References (up to 20 citations) and Figures and/or Tables (up to 3). The text should not exceed 2,000 words.

•Reviews: Authors are invited to submit a review article that provides concise and critical updates on a subject, and with around 100 references. The main purpose of reviews is to provide a concise, accurate introduction to the subject matter and inform the reader critically of the latest developments in the field. Review articles should be designed to give an interesting insight into a hot topic in Pharmacognosy, focusing on the key developments that have shaped a field rather than giving a very comprehensive overview of a very specific topic. They should be concise and include details of the search strategy used, such as time frame, search terms, used databases. A review should be an article that produces knowledge and not just a survey of the existing literature. The review must be a response to an initial question. Reviews of a particular herbal drug will be considered if they contain the newest issue and a perspective on future directions.

Authors are strongly recommended to prepare a manuscript using a A4-sized paper, double-spaced, with Times New Roman size-12 font, fully justified, with margins of 2 cm.

Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure the following:

• One author has been designated as the corresponding author with contact details: Institutional e-mail address; full postal address;

• ORCID ID for all authors;

• Authors’ contributions;

• All authors, with their respective email addresses, should be entered into the system.

• All necessary files have been uploaded: Graphical abstract, Manuscript; Include keywords; All figures with Legends; All tables (including titles, description, footnotes); and Supplemental files (if applicable).

• All figure and table citations in the text match the files provided;

• Manuscript has been 'spell checked' and 'grammar checked;

• All references mentioned in the Reference List are cited in the text, and vice versa;

• Permission has been obtained for use of copyrighted material from other sources (including the Internet);

• Relevant declarations of interest have been made;

• Journal policies detailed in this guide have been reviewed.

Additional information

• All plant, microorganism and marine organism materials used in the described research should be supported by an indication of the site (including GPS coordinates, if possible) and country of origin, the name of the person identifying the biological material and the location of the voucher specimen.

• Authors should be prepared to provide documentary evidence that approval for collection was afforded from an appropriate authority in the country of collection and, if applicable, to follow the rules concerning the biodiversity rights.

• The journal will not accept responsibility for research works that do not comply with the legislation of the country of residence of the author.

• We strongly recommend that authors avoid stating that the popular or traditional use of a certain herb was confirmed by pre-clinical, in vitro assays or in vivo tests using animals.

• The Revista Brasileira de Farmacognosia-Brazilian Journal of Pharmacognosy strongly encourages the submission of original works in which the experimental procedures were conducted taking into consideration green chemistry principles, such as by employing green solvents and environmental resource saving experimental designs in any step of the investigation.

• Evaluations using animal models to provide evidences for the pharmacological efficacy of plants do not fall into the areas of interest of the journal when polyphenol-rich plant extracts are involved and, therefore, making the results predictable.

• For the pharmacological studies to explore the therapeutic roles of polyphenols, such as antioxidant activity, antibacterial, antiviral, hepatoprotective, anti-inflammatory, antipyretic, anti-obesity, cardioprotective, neuroprotective, anti-hypertension, free radicals scavenger, and central nervous system stimulators, the journal will give preference to articles that make use of molecular tools over animal models for the characterization of the mechanism(s) of action of isolated pure compounds.

• For the pharmacobotanical studies, the use of DNA barcodes combined with chemical profile analysis (TLC and HPLC) would be the required approach to solve the problems of quality control of medicinal plants.

• The use of HPLC or UHPLC coupled to hybrid state-of-the-art mass spectrometers are becoming a key tool for the rapid and accurate analysis and dereplication of substances in complex plant matrices to rapidly estimate their pharmacological potential, making unnecessary the use of in vivo models to validate it where polyphenols are the major constituents.

• The Revista Brasileira de Farmacognosia-Brazilian Journal of Pharmacognosy explicitly encourages the submission of chemically characterized extracts by GC (volatile oils), HPLC and/or NMR.

• It is a mandatory requirement for authors to include copies of NMR spectra for all new compounds and tested bioactive compounds from a natural source in the Supporting Information.

• For works describing the structural elucidation of novel natural products, it is mandatory to include evidences for the absolute configuration.

The following immediate rejection criteria apply

i. the manuscript does not fall into the areas of interest of the journal;

ii. manuscripts not formatted in accordance with the standards of the journal, e.g., papers requiring English proof-reading can be refused without further editorial inspection.

iii. the manuscript results are preliminary, e.g., chemical analysis using different reagents for the identification of classes and types of secondary metabolites; pharmacobotanical studies without the use of DNA barcodes combined with chemical profile analysis;

iv. results not presenting chemically characterized extracts;

v. experimental work based on preliminary biological and pharmacological analysis for extracts without the identification of the active constituent(s) or dereplication of major constituents by GC (volatile compounds), HPLC or NMR.

vi. manuscripts reporting activity data without comparison with a reference, without a positive control/appropriate control or not based on adequate statistics;

vii. the biological source (e.g. plant, microorganism, marine organism etc.) is not clearly identified, authenticated and documented;

viii. experimental work on antioxidant activity of crude extracts without isolation, identification and content estimation of the active compounds; phenolic compounds are widely spread in nature and fully recognized as antioxidants or scavengers;

ix. experimental work on antimicrobial activity with crude extracts without isolation and identification of the active compounds, with large MIC values (μg/ml) for antimicrobial activity (≥250 μg/ml for plant extracts and ≥50 μg/ml for pure compounds) and without appropriate identification of culture collections/strain designation codes;

x. experimental work on volatile oils with only one sample of a single plant specimen with a single chromatographic analysis and without appropriate statistical analyses; without oil yield (%) and characterization and component quantification not undertaken using GC-MS-FID. Analyses of the retention indices of the components not calculated using n-alkane homologous series together with analyses of some of the isolated natural components. Biological activity of essential oil without chemical characterization;

xi. too preliminary data using in vitro or in vivo assays will not be acceptable if (i) no information on the type of activity is given; (ii) single dose or very high concentrations (must show dose–response studies); (iii) repetition of a simple bioassay (usually one assay with replicates); (iv) lack of appropriate controls (solvents; positive or negative substances according to the study); (v) no IC50 values (if applicable); (vi) predictable bioactivity is described (e.g., therapeutic roles of polyphenols);

xii. pharmacological efficacy of plants in animal models when the results involved polyphenol-rich plant extracts;

xiii. use of only the brine shrimp assay (Artemia salina) to access the toxicity of extracts;

xiv. isolation and bioassay of well-known compounds with small or no relationship to the activity, or to the medicinal use of the plant without clear justification;

xv. manuscripts reporting pharmacological or biological activities of crude extracts or phytopharmaceuticals without chemical and technical standardization. Standardization of the plant extracts is considered to be the complete description of manufacturing parameters such as granulometry, solvent-plant ratio, time of extraction, solvent composition etc., together with marker quantification and chromatographic fingerprint analyses by HPLC.

xvi. structural elucidation of novel natural products without complete spectroscopic and spectrometric analyses (NMR and HRMS) and evidences for the absolute configuration.

Graphical abstract

A Graphical abstract is mandatory for this journal. It should summarize the contents of the article in a concise and simple pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. This graphical abstract should capture the reader’s attention and, in conjunction with the manuscript title, should give the reader a quick visual impression of the essence of the manuscript without providing specific results. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: please provide an image with a minimum of 531 x times; 1328 pixels (h & w) or proportionally more. The image should be readable at a size of 5 x 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. BJP does not accept Graphical abstract using images of animals.

Title page

Title Page

Please use this template title page for providing the following information.

The title page should include:

  • The name(s) of the author(s)
  • A concise and informative title
  • The affiliation(s) of the author(s), i.e. institution, (department), city, (state), country
  • A clear indication and an active e-mail address of the corresponding author
  • If available, the 16-digit ORCID of the author(s)

If address information is provided with the affiliation(s) it will also be published.

For authors that are (temporarily) unaffiliated we will only capture their city and country of residence, not their e-mail address unless specifically requested.

Abstract

Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.

For life science journals only (when applicable)

Trial registration number and date of registration

Trial registration number, date of registration followed by “retrospectively registered”

Keywords

Please provide 4 to 6 keywords which can be used for indexing purposes.

Declarations

All manuscripts must contain the following sections under the heading 'Declarations'.

If any of the sections are not relevant to your manuscript, please include the heading and write 'Not applicable' for that section.

To be used for non-life science journals

Funding (information that explains whether and by whom the research was supported)

Conflicts of interest/Competing interests (include appropriate disclosures)

Availability of data and material (data transparency)

Code availability (software application or custom code)

Authors' contributions (optional: please review the submission guidelines from the journal whether statements are mandatory)

To be used for life science journals + articles with biological applications

Funding (information that explains whether and by whom the research was supported)

Conflicts of interest/Competing interests (include appropriate disclosures)

Ethics approval (include appropriate approvals or waivers)

Consent to participate (include appropriate statements)

Consent for publication (include appropriate statements)

Availability of data and material (data transparency)

Code availability (software application or custom code)

Authors' contributions (optional: please review the submission guidelines from the journal whether statements are mandatory)

Please see the relevant sections in the submission guidelines for further information as well as various examples of wording. Please revise/customize the sample statements according to your own needs.

Text

Text Formatting

Manuscripts should be submitted in Word.

  • Use a normal, plain font (e.g., 10-point Times Roman) for text.
  • Use italics for emphasis.
  • Use the automatic page numbering function to number the pages.
  • Do not use field functions.
  • Use tab stops or other commands for indents, not the space bar.
  • Use the table function, not spreadsheets, to make tables.
  • Use the equation editor or MathType for equations.
  • Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).

Manuscripts with mathematical content can also be submitted in LaTeX.

LaTeX macro package (Download zip, 188 kB)

Headings

Please use no more than three levels of displayed headings.

Abbreviations

Abbreviations should be defined at first mention and used consistently thereafter.

Footnotes

Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.

Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.

Always use footnotes instead of endnotes.

Acknowledgments

Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organizations should be written in full.

References

Citation

Cite references in the text by name and year in parentheses. Some examples:

  • Negotiation research spans many disciplines (Thompson 1990).
  • This result was later contradicted by Becker and Seligman (1996).
  • This effect has been widely studied (Abbott 1991; Barakat et al. 1995a, b; Kelso and Smith 1998; Medvec et al. 1999, 2000).

Reference list

The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.

Reference list entries should be alphabetized by the last names of the first author of each work. Order multi-author publications of the same first author alphabetically with respect to second, third, etc. author. Publications of exactly the same author(s) must be ordered chronologically.

  • Journal article

    Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L (2009) Effect of high intensity intermittent training on heart rate variability in prepubescent children. Eur J Appl Physiol 105:731-738. https://doi.org/10.1007/s00421-008-0955-8

    Ideally, the names of all authors should be provided, but the usage of “et al” in long author lists will also be accepted:

    Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. N Engl J Med 965:325–329

  • Article by DOI

    Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med. https://doi.org/10.1007/s001090000086

  • Book

    South J, Blass B (2001) The future of modern genomics. Blackwell, London

  • Book chapter

    Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern genomics, 3rd edn. Wiley, New York, pp 230-257

  • Online document

    Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007

  • Dissertation

    Trent JW (1975) Experimental acute renal failure. Dissertation, University of California

Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see

ISSN LTWA

If you are unsure, please use the full journal title.

For authors using EndNote, Springer provides an output style that supports the formatting of in-text citations and reference list.

EndNote style (Download zip, 3 kB)

Tables

  • All tables are to be numbered using Arabic numerals.
  • Tables should always be cited in text in consecutive numerical order.
  • For each table, please supply a table caption (title) explaining the components of the table.
  • Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
  • Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.

Artwork and Illustrations Guidelines

Electronic Figure Submission

  • Supply all figures electronically.
  • Indicate what graphics program was used to create the artwork.
  • For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MSOffice files are also acceptable.
  • Vector graphics containing fonts must have the fonts embedded in the files.
  • Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.

Line Art

  • Definition: Black and white graphic with no shading.
  • Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
  • All lines should be at least 0.1 mm (0.3 pt) wide.
  • Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.
  • Vector graphics containing fonts must have the fonts embedded in the files.

Halftone Art

  • Definition: Photographs, drawings, or paintings with fine shading, etc.
  • If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.
  • Halftones should have a minimum resolution of 300 dpi.

Combination Art

  • Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
  • Combination artwork should have a minimum resolution of 600 dpi.

Color Art

  • Color art is free of charge for online publication.
  • If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
  • If the figures will be printed in black and white, do not refer to color in the captions.
  • Color illustrations should be submitted as RGB (8 bits per channel).

Figure Lettering

  • To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
  • Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).
  • Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
  • Avoid effects such as shading, outline letters, etc.
  • Do not include titles or captions within your illustrations.

Figure Numbering

  • All figures are to be numbered using Arabic numerals.
  • Figures should always be cited in text in consecutive numerical order.
  • Figure parts should be denoted by lowercase letters (a, b, c, etc.).
  • If an appendix appears in your article and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures,"A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, be numbered separately.

Figure Captions

  • Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
  • Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
  • No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
  • Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
  • Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

Figure Placement and Size

  • Figures should be submitted separately from the text, if possible.
  • When preparing your figures, size figures to fit in the column width.
  • For large-sized journals the figures should be 84 mm (for double-column text areas), or 174 mm (for single-column text areas) wide and not higher than 234 mm.
  • For small-sized journals, the figures should be 119 mm wide and not higher than 195 mm.

Permissions

If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

Accessibility

In order to give people of all abilities and disabilities access to the content of your figures, please make sure that

  • All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware)
  • Patterns are used instead of or in addition to colors for conveying information (colorblind users would then be able to distinguish the visual elements)
  • Any figure lettering has a contrast ratio of at least 4.5:1

Electronic Supplementary Material

Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online along with an article or a book chapter. This feature can add dimension to the author's article, as certain information cannot be printed or is more convenient in electronic form.

Before submitting research datasets as electronic supplementary material, authors should read the journal’s Research data policy. We encourage research data to be archived in data repositories wherever possible.

Submission

  • Supply all supplementary material in standard file formats.
  • Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
  • To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.

Audio, Video, and Animations

  • Aspect ratio: 16:9 or 4:3
  • Maximum file size: 25 GB
  • Minimum video duration: 1 sec
  • Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts, m4v, 3gp

Text and Presentations

  • Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
  • A collection of figures may also be combined in a PDF file.

Spreadsheets

  • Spreadsheets should be submitted as .csv or .xlsx files (MS Excel).

Specialized Formats

  • Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.

Collecting Multiple Files

  • It is possible to collect multiple files in a .zip or .gz file.

Numbering

  • If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables.
  • Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", “... additional data are given in Online Resource 4”.
  • Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.

Captions

  • For each supplementary material, please supply a concise caption describing the content of the file.

Processing of supplementary files

  • Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting.

Accessibility

In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that

  • The manuscript contains a descriptive caption for each supplementary material
  • Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)

After Acceptance

Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order OpenChoice and offprints.

Once the Author Query Application has been completed, your article will be processed and you will receive the proofs.

Copyright transfer

Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.

Offprints

Offprints can be ordered by the corresponding author.

Color illustrations

Publication of color illustrations is free of charge.

Proof reading

The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.

After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.

Online First

The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.

Open Choice

Open Choice allows you to publish open access in more than 1850 Springer Nature journals, making your research more visible and accessible immediately on publication.

Article processing charges (APCs) vary by journal – view the full list

Benefits:

  • Increased researcher engagement: Open Choice enables access by anyone with an internet connection, immediately on publication.
  • Higher visibility and impact: In Springer hybrid journals, OA articles are accessed 4 times more often on average, and cited 1.7 more times on average*.

  • Easy compliance with funder and institutional mandates: Many funders require open access publishing, and some take compliance into account when assessing future grant applications.

It is easy to find funding to support open access – please see our funding and support pages for more information.

*) Within the first three years of publication. Springer Nature hybrid journal OA impact analysis, 2018.

Open Choice

Funding and Support pages

Copyright and license term – CC BY

Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.

Find more about the license agreement

Research Data Policy

The journal encourages authors, where possible and applicable, to deposit data that support the findings of their research in a public repository. Authors and editors who do not have a preferred repository should consult Springer Nature’s list of repositories and research data policy.

List of Repositories

Research Data Policy

General repositories - for all types of research data - such as figshare and Dryad may also be used.

Datasets that are assigned digital object identifiers (DOIs) by a data repository may be cited in the reference list. Data citations should include the minimum information recommended by DataCite: authors, title, publisher (repository name), identifier.

DataCite

Springer Nature provides a research data policy support service for authors and editors, which can be contacted at researchdata@springernature.com.

This service provides advice on research data policy compliance and on finding research data repositories. It is independent of journal, book and conference proceedings editorial offices and does not advise on specific manuscripts.

Helpdesk

Scientific style

Please always use internationally accepted signs and symbols for units (SI units).

Conflicts of Interest / Competing Interests

Authors are requested to disclose interests that are directly or indirectly related to the work submitted for publication. Interests within the last 3 years of beginning the work (conducting the research and preparing the work for submission) should be reported. Interests outside the 3-year time frame must be disclosed if they could reasonably be perceived as influencing the submitted work. Disclosure of interests provides a complete and transparent process and helps readers form their own judgments of potential bias. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate.

Interests that should be considered and disclosed but are not limited to the following:

Funding: Research grants from funding agencies (please give the research funder and the grant number) and/or research support (including salaries, equipment, supplies, reimbursement for attending symposia, and other expenses) by organizations that may gain or lose financially through publication of this manuscript.

Employment: Recent (while engaged in the research project), present or anticipated employment by any organization that may gain or lose financially through publication of this manuscript. This includes multiple affiliations (if applicable).

Financial interests: Stocks or shares in companies (including holdings of spouse and/or children) that may gain or lose financially through publication of this manuscript; consultation fees or other forms of remuneration from organizations that may gain or lose financially; patents or patent applications whose value may be affected by publication of this manuscript.

It is difficult to specify a threshold at which a financial interest becomes significant, any such figure is necessarily arbitrary, so one possible practical guideline is the following: "Any undeclared financial interest that could embarrass the author were it to become publicly known after the work was published."

Non-financial interests: In addition, authors are requested to disclose interests that go beyond financial interests that could impart bias on the work submitted for publication such as professional interests, personal relationships or personal beliefs (amongst others). Examples include, but are not limited to: position on editorial board, advisory board or board of directors or other type of management relationships; writing and/or consulting for educational purposes; expert witness; mentoring relations; and so forth.

Primary research articles require a disclosure statement. Review articles present an expert synthesis of evidence and may be treated as an authoritative work on a subject. Review articles therefore require a disclosure statement. Other article types such as editorials, book reviews, comments (amongst others) may, dependent on their content, require a disclosure statement. If you are unclear whether your article type requires a disclosure statement, please contact the Editor-in-Chief.

Please note that, in addition to the above requirements, funding information (given that funding is a potential conflict of interest (as mentioned above)) needs to be disclosed upon submission of the manuscript in the peer review system. This information will automatically be added to the Record of CrossMark, however it is not added to the manuscript itself. Under ‘summary of requirements’ (see below) funding information should be included in the ‘Declarations’ section.

Summary of requirements

The above should be summarized in a statement and included on a title page that is separate from the manuscript with a section entitled “Declarations” when submitting a paper. Having all statements in one place allows for a consistent and unified review of the information by the Editor-in-Chief and/or peer reviewers and may speed up the handling of the paper. Declarations include Funding, Conflicts of interest/competing interests, Ethics approval, Consent, Data, Materials and/or Code availability and Authors’ contribution statements. Please use the title page for providing the statements.

Once and if the paper is accepted for publication, the production department will put the respective statements in a distinctly identified section clearly visible for readers.

Please see the various examples of wording below and revise/customize the sample statements according to your own needs.

When all authors have the same (or no) conflicts and/or funding it is sufficient to use one blanket statement.

Provide “Funding” as a heading (see template)

  • Partial financial support was received from [...]
  • The research leading to these results received funding from […] under Grant Agreement No[…].
  • This study was funded by […]
  • This work was supported by […] (Grant numbers […] and […]

In case of no funding:

  • The authors did not receive support from any organization for the submitted work.
  • No funding was received to assist with the preparation of this manuscript.
  • No funding was received for conducting this study.
  • No funds, grants, or other support was received.

Provide “Conflicts of interest/Competing interests” as a header (see template)

  • Financial interests: Author A has received research support from Company A. Author B has received a speaker honorarium from Company Wand owns stock in Company X. Author C is consultant to company Y.

    Non-financial interests: Author C is an unpaid member of committee Z.

  • Financial interests: The authors declare they have no financial interests.

    Non-financial interests: Author A is on the board of directors of Y and receives no compensation as member of the board of directors.

  • Financial interests: Author A received a speaking fee from Y for Z. Author B receives a salary from association X. X where s/he is the Executive Director.

    Non-financial interests: none.

  • Financial interests: Author A and B declare they have no financial interests. Author C has received speaker and consultant honoraria from Company M and Company N. Dr. C has received speaker honorarium and research funding from Company M and Company O. Author D has received travel support from Company O.

    Non-financial interests: Author D has served on advisory boards for Company M, Company N and Company O.

When authors have nothing to declare the following statement may be used:

  • The authors have no relevant financial or non-financial interests to disclose.
  • The authors have no conflicts of interest to declare that are relevant to the content of this article.
  • All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.
  • The authors have no financial or proprietary interests in any material discussed in this article.

Authors are responsible for correctness of the statements provided in the manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right to reject submissions that do not meet the guidelines described in this section.

Research involving human participants, their data or biological material

Ethics approval

When reporting a study that involved human participants, their data or biological material, authors should include a statement that confirms that the study was approved (or granted exemption) by the appropriate institutional and/or national research ethics committee (including the name of the ethics committee) and certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. If doubt exists whether the research was conducted in accordance with the 1964 Helsinki Declaration or comparable standards, the authors must explain the reasons for their approach, and demonstrate that an independent ethics committee or institutional review board explicitly approved the doubtful aspects of the study. If a study was granted exemption from requiring ethics approval, this should also be detailed in the manuscript (including the reasons for the exemption).

Retrospective ethics approval

If a study has not been granted ethics committee approval prior to commencing, retrospective ethics approval usually cannot be obtained and it may not be possible to consider the manuscript for peer review. The decision on whether to proceed to peer review in such cases is at the Editor's discretion.

Ethics approval for retrospective studies

Although retrospective studies are conducted on already available data or biological material (for which formal consent may not be needed or is difficult to obtain) ethics approval may be required dependent on the law and the national ethical guidelines of a country. Authors should check with their institution to make sure they are complying with the specific requirements of their country.

Ethics approval for case studies

Case reports require ethics approval. Most institutions will have specific policies on this subject. Authors should check with their institution to make sure they are complying with the specific requirements of their institution and seek ethics approval where needed. Authors should be aware to secure informed consent from the individual (or parent or guardian if the participant is a minor or incapable) See also section on Informed Consent.

Cell lines

If human cells are used, authors must declare in the manuscript: what cell lines were used by describing the source of the cell line, including when and from where it was obtained, whether the cell line has recently been authenticated and by what method. If cells were bought from a life science company the following need to be given in the manuscript: name of company (that provided the cells), cell type, number of cell line, and batch of cells.

It is recommended that authors check the NCBI database for misidentification and contamination of human cell lines. This step will alert authors to possible problems with the cell line and may save considerable time and effort.

Further information is available from the International Cell Line Authentication Committee (ICLAC).

Authors should include a statement that confirms that an institutional or independent ethics committee (including the name of the ethics committee) approved the study and that informed consent was obtained from the donor or next of kin.

Research Resource Identifiers (RRID)

Research Resource Identifiers (RRID) are persistent unique identifiers (effectively similar to a DOI) for research resources. This journal encourages authors to adopt RRIDs when reporting key biological resources (antibodies, cell lines, model organisms and tools) in their manuscripts.

Examples:

Organism: Filip1tm1a(KOMP)Wtsi RRID:MMRRC_055641-UCD

Cell Line: RST307 cell line RRID:CVCL_C321

Antibody: Luciferase antibody DSHB Cat# LUC-3, RRID:AB_2722109

Plasmid: mRuby3 plasmid RRID:Addgene_104005

Software: ImageJ Version 1.2.4 RRID:SCR_003070

RRIDs are provided by the Resource Identification Portal. Many commonly used research resources already have designated RRIDs. The portal also provides authors links so that they can quickly register a new resource and obtain an RRID.

Clinical Trial Registration

The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to assess, improve, maintain, promote or modify health, functioning or health conditions” and a health-related outcome is generally defined as a change in the health of a person or population as a result of an intervention.

To ensure the integrity of the reporting of patient-centered trials, authors must register prospective clinical trials (phase II to IV trials) in suitable publicly available repositories. For example www.clinicaltrials.gov or any of the primary registries that participate in the WHO International Clinical Trials Registry Platform.

The trial registration number (TRN) and date of registration should be included as the last line of the manuscript abstract.

For clinical trials that have not been registered prospectively, authors are encouraged to register retrospectively to ensure the complete publication of all results. The trial registration number (TRN), date of registration and the words 'retrospectively registered’ should be included as the last line of the manuscript abstract.

Purely observational trials will not require registration.

Standards of reporting

Springer Nature advocates complete and transparent reporting of biomedical and biological research and research with biological applications. Authors are recommended to adhere to the minimum reporting guidelines hosted by the EQUATOR Network when preparing their manuscript.

Exact requirements may vary depending on the journal; please refer to the journal’s Instructions for Authors.

Checklists are available for a number of study designs, including:

Randomised trials (CONSORT) and Study protocols (SPIRIT)

Observational studies (STROBE)

Systematic reviews and meta-analyses (PRISMA) and protocols (Prisma-P)

Diagnostic/prognostic studies (STARD) and (TRIPOD)

Case reports (CARE)

Clinical practice guidelines (AGREE) and (RIGHT)

Qualitative research (SRQR) and (COREQ)

Animal pre-clinical studies (ARRIVE)

Quality improvement studies (SQUIRE)

Economic evaluations (CHEERS)

Summary of requirements

The above should be summarized in a statement and placed in a ‘Declarations’ section before the reference list under a heading of ‘Ethics approval’.

Examples of statements to be used when ethics approval has been obtained:

• All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the Medical University of A (No. ...).

• This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University B (Date.../No. ...).

• Approval was obtained from the ethics committee of University C. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

• The questionnaire and methodology for this study was approved by the Human Research Ethics committee of the University of D (Ethics approval number: ...).

Examples of statements to be used for a retrospective study:

• Ethical approval was waived by the local Ethics Committee of University A in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.

• This research study was conducted retrospectively from data obtained for clinical purposes. We consulted extensively with the IRB of XYZ who determined that our study did not need ethical approval. An IRB official waiver of ethical approval was granted from the IRB of XYZ.

• This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of University B approved this study.

Examples of statements to be used when no ethical approval is required/exemption granted:

• This is an observational study. The XYZ Research Ethics Committee has confirmed that no ethical approval is required.

• The data reproduced from Article X utilized human tissue that was procured via our Biobank AB, which provides de-identified samples. This study was reviewed and deemed exempt by our XYZ Institutional Review Board. The BioBank protocols are in accordance with the ethical standards of our institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Authors are responsible for correctness of the statements provided in the manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right to reject submissions that do not meet the guidelines described in this section.

All individuals have individual rights that are not to be infringed. Individual participants in studies have, for example, the right to decide what happens to the (identifiable) personal data gathered, to what they have said during a study or an interview, as well as to any photograph that was taken. This is especially true concerning images of vulnerable people (e.g. minors, patients, refugees, etc) or the use of images in sensitive contexts. In many instances authors will need to secure written consent before including images.

Identifying details (names, dates of birth, identity numbers, biometrical characteristics (such as facial features, fingerprint, writing style, voice pattern, DNA or other distinguishing characteristic) and other information) of the participants that were studied should not be published in written descriptions, photographs, and genetic profiles unless the information is essential for scholarly purposes and the participant (or parent/guardian if the participant is a minor or incapable or legal representative) gave written informed consent for publication. Complete anonymity is difficult to achieve in some cases. Detailed descriptions of individual participants, whether of their whole bodies or of body sections, may lead to disclosure of their identity. Under certain circumstances consent is not required as long as information is anonymized and the submission does not include images that may identify the person.

Informed consent for publication should be obtained if there is any doubt. For example, masking the eye region in photographs of participants is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic profiles, authors should provide assurance that alterations do not distort meaning.

Exceptions where it is not necessary to obtain consent:

• Images such as x rays, laparoscopic images, ultrasound images, brain scans, pathology slides unless there is a concern about identifying information in which case, authors should ensure that consent is obtained.

• Reuse of images: If images are being reused from prior publications, the Publisher will assume that the prior publication obtained the relevant information regarding consent. Authors should provide the appropriate attribution for republished images.

Consent and already available data and/or biologic material

Regardless of whether material is collected from living or dead patients, they (family or guardian if the deceased has not made a pre-mortem decision) must have given prior written consent. The aspect of confidentiality as well as any wishes from the deceased should be respected.

Data protection, confidentiality and privacy

When biological material is donated for or data is generated as part of a research project authors should ensure, as part of the informed consent procedure, that the participants are made aware what kind of (personal) data will be processed, how it will be used and for what purpose. In case of data acquired via a biobank/biorepository, it is possible they apply a broad consent which allows research participants to consent to a broad range of uses of their data and samples which is regarded by research ethics committees as specific enough to be considered “informed”. However, authors should always check the specific biobank/biorepository policies or any other type of data provider policies (in case of non-bio research) to be sure that this is the case.

Consent to Participate

For all research involving human subjects, freely-given, informed consent to participate in the study must be obtained from participants (or their parent or legal guardian in the case of children under 16) and a statement to this effect should appear in the manuscript. In the case of articles describing human transplantation studies, authors must include a statement declaring that no organs/tissues were obtained from prisoners and must also name the institution(s)/clinic(s)/department(s) via which organs/tissues were obtained. For manuscripts reporting studies involving vulnerable groups where there is the potential for coercion or where consent may not have been fully informed, extra care will be taken by the editor and may be referred to the Springer Nature Research Integrity Group.

Consent to Publish

Individuals may consent to participate in a study, but object to having their data published in a journal article. Authors should make sure to also seek consent from individuals to publish their data prior to submitting their paper to a journal. This is in particular applicable to case studies. A consent to publish form can be found

here. (Download docx, 36 kB)

Summary of requirements

The above should be summarized in a statement and placed in a ‘Declarations’ section before the reference list under a heading of ‘Consent to participate’ and/or ‘Consent to publish’. Other declarations include Funding, Conflicts of interest/competing interests, Ethics approval, Consent, Data and/or Code availability and Authors’ contribution statements.

Please see the various examples of wording below and revise/customize the sample statements according to your own needs.

Sample statements for "Consent to participate":

Informed consent was obtained from all individual participants included in the study.

Informed consent was obtained from legal guardians.

Written informed consent was obtained from the parents.

Verbal informed consent was obtained prior to the interview.

Sample statements for “Consent to publish”:

The authors affirm that human research participants provided informed consent for publication of the images in Figure(s) 1a, 1b and 1c.

The participant has consented to the submission of the case report to the journal.

Patients signed informed consent regarding publishing their data and photographs.

Sample statements if identifying information about participants is available in the article:

Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

Authors are responsible for correctness of the statements provided in the manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right to reject submissions that do not meet the guidelines described in this section.

Images will be removed from publication if authors have not obtained informed consent or the paper may be removed and replaced with a notice explaining the reason for removal.

Authorship principles

These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to.

Authorship clarified

The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before the work is submitted.

The Publisher does not prescribe the kinds of contributions that warrant authorship. It is recommended that authors adhere to the guidelines for authorship that are applicable in their specific research field. In absence of specific guidelines it is recommended to adhere to the following guidelines*:

All authors whose names appear on the submission

1) made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work;

2) drafted the work or revised it critically for important intellectual content;

3) approved the version to be published; and

4) agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

* Based on/adapted from:

ICMJE, Defining the Role of Authors and Contributors,

Transparency in authors’ contributions and responsibilities to promote integrity in scientific publication, McNutt at all, PNAS February 27, 2018

Disclosures and declarations

All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate).

The decision whether such information should be included is not only dependent on the scope of the journal, but also the scope of the article. Work submitted for publication may have implications for public health or general welfare and in those cases it is the responsibility of all authors to include the appropriate disclosures and declarations.

Data transparency

All authors are requested to make sure that all data and materials as well as software application or custom code support their published claims and comply with field standards. Please note that journals may have individual policies on (sharing) research data in concordance with disciplinary norms and expectations.

Role of the Corresponding Author

One author is assigned as Corresponding Author and acts on behalf of all co-authors and ensures that questions related to the accuracy or integrity of any part of the work are appropriately addressed.

The Corresponding Author is responsible for the following requirements:

  • ensuring that all listed authors have approved the manuscript before submission, including the names and order of authors;
  • managing all communication between the Journal and all co-authors, before and after publication;*
  • providing transparency on re-use of material and mention any unpublished material (for example manuscripts in press) included in the manuscript in a cover letter to the Editor;
  • making sure disclosures, declarations and transparency on data statements from all authors are included in the manuscript as appropriate (see above).

* The requirement of managing all communication between the journal and all co-authors during submission and proofing may be delegated to a Contact or Submitting Author. In this case please make sure the Corresponding Author is clearly indicated in the manuscript.

Author contributions

In absence of specific instructions and in research fields where it is possible to describe discrete efforts, the Publisher recommends authors to include contribution statements in the work that specifies the contribution of every author in order to promote transparency. These contributions should be listed at the separate title page.

Examples of such statement(s) are shown below:

• Free text:

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by [full name], [full name] and [full name]. The first draft of the manuscript was written by [full name] and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Example: CRediT taxonomy:

• Conceptualization: [full name], …; Methodology: [full name], …; Formal analysis and investigation: [full name], …; Writing - original draft preparation: [full name, …]; Writing - review and editing: [full name], …; Funding acquisition: [full name], …; Resources: [full name], …; Supervision: [full name],….

For review articles where discrete statements are less applicable a statement should be included who had the idea for the article, who performed the literature search and data analysis, and who drafted and/or critically revised the work.

For articles that are based primarily on the student’s dissertation or thesis, it is recommended that the student is usually listed as principal author:

A Graduate Student’s Guide to Determining Authorship Credit and Authorship Order, APA Science Student Council 2006

Affiliation

The primary affiliation for each author should be the institution where the majority of their work was done. If an author has subsequently moved, the current address may additionally be stated. Addresses will not be updated or changed after publication of the article.

Changes to authorship

Authors are strongly advised to ensure the correct author group, the Corresponding Author, and the order of authors at submission. Changes of authorship by adding or deleting authors, and/or changes in Corresponding Author, and/or changes in the sequence of authors are not accepted after acceptance of a manuscript.

  • Please note that author names will be published exactly as they appear on the accepted submission!

Please make sure that the names of all authors are present and correctly spelled, and that addresses and affiliations are current.

Adding and/or deleting authors at revision stage are generally not permitted, but in some cases it may be warranted. Reasons for these changes in authorship should be explained. Approval of the change during revision is at the discretion of the Editor-in-Chief. Please note that journals may have individual policies on adding and/or deleting authors during revision stage.

Author identification

Authors are recommended to use their ORCID ID when submitting an article for consideration or acquire an ORCID ID via the submission process.

Deceased or incapacitated authors

For cases in which a co-author dies or is incapacitated during the writing, submission, or peer-review process, and the co-authors feel it is appropriate to include the author, co-authors should obtain approval from a (legal) representative which could be a direct relative.

Authorship issues or disputes

In the case of an authorship dispute during peer review or after acceptance and publication, the Journal will not be in a position to investigate or adjudicate. Authors will be asked to resolve the dispute themselves. If they are unable the Journal reserves the right to withdraw a manuscript from the editorial process or in case of a published paper raise the issue with the authors’ institution(s) and abide by its guidelines.

Confidentiality

Authors should treat all communication with the Journal as confidential which includes correspondence with direct representatives from the Journal such as Editors-in-Chief and/or Handling Editors and reviewers’ reports unless explicit consent has been received to share information.

Editorial procedure

Single-blind peer review

This journal follows a single-blind reviewing procedure.

English Language Support

For editors and reviewers to accurately assess the work presented in your manuscript you need to ensure the English language is of sufficient quality to be understood. If you need help with writing in English you should consider:

  • Asking a colleague who is a native English speaker to review your manuscript for clarity.
  • Visiting the English language tutorial which covers the common mistakes when writing in English.
  • Using a professional language editing service where editors will improve the English to ensure that your meaning is clear and identify problems that require your review. Two such services are provided by our affiliates Nature Research Editing Service and American Journal Experts. Springer authors are entitled to a 10% discount on their first submission to either of these services, simply follow the links below
.

English language tutorial

Nature Research Editing Service

American Journal Experts

Please note that the use of a language editing service is not a requirement for publication in this journal and does not imply or guarantee that the article will be selected for peer review or accepted.

If your manuscript is accepted it will be checked by our copyeditors for spelling and formal style before publication.

Open access publishing

Revista Brasileira de Farmacognosia publishes open access articles. Authors of open access articles published in this journal retain the copyright of their articles and are free to reproduce and disseminate their work.

Visit our Open access publishing page to learn more.